Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06400810 · ClinicalTrials.gov registry record
Proximal Risk for Suicide in Adolescents
A clinical trial of Suicide and Mental Health Issue, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- 144
- Enrollment target
- 1
- Study location
NCT06400810: Recruiting study of Suicide and Mental Health Issue, sponsored by Oregon Health and Science University.
NCT06400810 is a study of Suicide and Mental Health Issue that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 144 participants, below the 6,988-participant average among 92 other Suicide trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06400810, a study of Suicide and Mental Health Issue, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- 144 participants
- Enrollment target
- 1
- Study location
Study Summary
The central hypothesis is that biometric data can continuously monitor and allow for early identification/intervention of escalating suicidal symptoms. The rationale is that improved outpatient monitoring through wearable technology can create a more objective platform to provide the ability to identify a worsening condition and utilize patient-specific just-in-time therapeutics developed with mental health providers for suicidal adolescents.
Primary Outcome
Prediction of Suicidality outcome measured by the Columbia Suicide Severity scale (higher score means more suicidal)
Conditions Studied
Interventions
- DEVICE Analog Devices Inc.
Study Locations (1)
Oregon
- OHSU - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2026-07-01 |
What NCT06400810 shows while recruiting
NCT06400810 is an observational study that tracks outcomes without assigning an intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 6,988-participant average among 92 other Suicide trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Suicide appearing as the primary indexed condition, and to 1 intervention - of which Analog Devices Inc. is the first listed.
NCT06400810 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT06400810 about?
NCT06400810 is a clinical study titled "Proximal Risk for Suicide in Adolescents". The central hypothesis is that biometric data can continuously monitor and allow for early identification/intervention of escalating suicidal symptoms. The rationale is that improved outpatient monitoring through wearable technology can create a more objective platform to provide the ability to iden...
What is the current status of trial NCT06400810?
This trial is currently recruiting. The enrollment target is 144 participants. The study started on 2023-06-15. Estimated completion is 2026-07-01.
What conditions does trial NCT06400810 study?
This clinical trial studies the following conditions: Suicide, Mental Health Issue.
What interventions are being tested in trial NCT06400810?
The interventions under investigation include: Analog Devices Inc. (DEVICE).
Who is sponsoring clinical trial NCT06400810?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06400810 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Suicide
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06400810's enrollment target sits among peer trials
144 39th of 92 higher than 54 of 92 other Suicide trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Suicide trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Randomized Clinical Trial of Supplementing Brief Psychotherapy With a Mobile App
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
-
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
RECRUITING · NA
-
Suicide Specific Rumination in Veterans
RECRUITING · NA
-
Real-time Examination of Skills and Coping Use in Teen's Everyday Lives
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI